Phathom Pharmaceuticals (PHAT) Net Income towards Common Stockholders (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$48.0 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 49.13% year-over-year to -$48.0 million in Q1 2026; TTM through Mar 2026 was -$207.7 million, a 45.18% increase from a year earlier, with the FY2025 full-year figure at -$233.5 million, up 54.9% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$48.0 million, down from -$21.1 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for PHAT reached as high as -$21.1 million in Q4 2025 and fell as low as -$118.7 million in Q3 2024.
• Historically, Net Income towards Common Stockholders has averaged -$64.0 million across 5 years, with a median of -$51.1 million in 2022.
• Across the five-year window, Net Income towards Common Stockholders plunged 175.73% in 2024 and soared 71.62% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$49.2 million in 2022, then tumbled by 103.99% to -$100.3 million in 2023, then rose by 25.7% to -$74.5 million in 2024, then surged by 71.62% to -$21.1 million in 2025, then plunged by 126.89% to -$48.0 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$48.0 million in Q1 2026, -$21.1 million in Q4 2025, and -$55.2 million in Q3 2025.